DCTH Delcath Systems, Inc. - Common Stock
NASDAQ · Health Care · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 6, 2026
$15,13
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$8,1252 haftanın en düşüğü
$17,4252 haftanın en yükseği
Piyasa Değeri (MRQ)
$524M
P/E (TTM)
1513.0
Hisse Başına Kâr (TTM)
$0.01
Gelir (TTM)
$95M
rozetleriniz
52 Haftlık Aralık
$8–$17
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$24
P/E
1513.0
ROE
0.47%
Net Kâr Marjı
0.56%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
DCTH Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$15.13
Piyasa Değeri (MRQ)
$524M
P/E (TTM)
1513.0
Hisse Başına Kâr (TTM)
$0.01
Gelir (TTM)
$95M
ROE (TTM)
0.47%
52 Haftlık Aralık
$8–$17
DCTH Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 24 Aralık 2019 | 1-for-700 | Ters |
Delcath Systems, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
## Phase III melanoma trial enrolling
University of Pittsburgh Medical Center
National Cancer Institute in Bethesda, Maryland
Albany Medical Center in Albany, New York
John Wayne Cancer Center in Santa Monica, California
Moffitt Cancer Center in Tampa, Florida
Morristown Memorial Hospital in Morristown, New Jersey
Providence Cancer Center in Portland, Oregon
St. Luke's Cancer Center of Bethlehem, Pennsylvania
Swedish Medical Center in Englewood, Colorado
University of Maryland Medical Center in Baltimore, Maryland
University of Texas Medical Branch in Galveston, Texas
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealth Care
endüstriHealth Care
çalışanlar156
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$85M2016-12-31 → 2025-12-31
Hisse Başına Kâr$0.072017-12-31 → 2025-12-31
Serbest Nakit Akışı$21M2018-12-31 → 2025-12-31
Net kar marjı0.56%2022-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | DCTH | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 1513.05Y ort. ≈25.4 | ≈25.4 | · | · | |
| F/S (TTM) | 5.55Y ort. ≈17.7 | ≈17.7 | 3.7 | Aşırı değerli | |
| F/D (MRQ) | 4.35Y ort. ≈3.0 | ≈3.0 | 3.4 | Aşırı değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | 29.95Y ort. ≈-2.2 | ≈-2.2 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 26.85Y ort. ≈-2.5 | ≈-2.5 | 18.5 | Düşük değerli | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 4.75Y ort. ≈5.0 | ≈5.0 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | DCTH | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Brüt Kar Marjı (TTM) | 87.1%5Y ort. ≈78.4% | ≈78.4% | 73.6% | En üst düzey | |
| Faaliyet Kâr Marjı (TTM) | -1.9%5Y ort. ≈-781.7% | ≈-781.7% | -8.2% | En üst düzey | |
| EBITDA Margin (FAVÖK Marjı) | 0.77%5Y ort. ≈-781.7% | ≈-781.7% | -5.0% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | 1.4%5Y ort. ≈-929.6% | ≈-929.6% | -11.3% | En üst düzey | |
| Net Kâr Marjı (TTM) | 0.56%5Y ort. ≈-929.8% | ≈-929.8% | -13.1% | En üst düzey | |
| ROA (TTM) | 0.42%5Y ort. ≈-86.2% | ≈-86.2% | -16.0% | En üst düzey | |
| ROE (TTM) | 0.47%5Y ort. ≈27.9% | ≈27.9% | -25.7% | En üst düzey | |
| ROIC | 0.46%5Y ort. ≈22.6% | ≈22.6% | -23.7% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | DCTH | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 9.85Y ort. ≈6.3 | ≈6.3 | 3.5 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 5.05Y ort. ≈3.5 | ≈3.5 | 2.2 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | DCTH | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 129.1%5Y ort. ≈445.8% | ≈445.8% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 215.3% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | DCTH | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.95Y ort. ≈0.4 | ≈0.4 | 0.8 | Aynı seviyede | |
| Inventory Turnover (Stok Devir Hızı) | 1.45Y ort. ≈0.8 | ≈0.8 | 1.7 | Zayıf | |
| Receivables Turnover (Alacak Devir Hızı) | 7.55Y ort. ≈8.6 | ≈8.6 | 7.3 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$546.4K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
88.6%
Sonraki Rapor
Kas 02, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 10, 2026 | $0.07 | $-0.09 | 176.3% |
| 31 Mart 2026 | May 12, 2026 | $-0.03 | $-0.09 | 66.1% |
| 31 Aralık 2025 | $-0.05 | $-0.06 | 20.5% | |
| 30 Eylül 2025 | $0.02 | $0.02 | -2.0% | |
| 30 Haziran 2025 | $0.07 | $0.03 | 174.5% | |
| 31 Mart 2025 | $0.03 | $0.02 | 96.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $37M | $2M | $3M | $4M | · | · | · | $3M | $2M | $2M | $1M | |
| Cost of Revenue | $12M | $6M | $635.0K | $686.0K | $671.0K | $640.0K | $719.0K | $1M | $701.0K | $550.0K | $462.0K | $291.0K | |
| Gross Profit | $73M | $31M | $1M | $2M | $3M | $1M | $861.0K | $2M | $2M | $1M | $1M | $778.0K | |
| R&D Expense | $29M | $14M | $18M | $19M | $14M | $11M | $9M | $20M | $10M | $8M | $6M | $4M | |
| SG&A Expense | $44M | $30M | $22M | $17M | $14M | $11M | $11M | $10M | $10M | $9M | $10M | $16M | |
| Operating Expenses | $73M | $43M | $40M | $36M | $27M | $22M | $21M | $29M | $20M | $18M | $16M | $20M | |
| Operating Income | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | $-18M | $-16M | $-15M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | · | $22M | $14M | $67.0K | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $17.0K | $9.0K | $5.0K | |
| Other Non-op | $-70.0K | $-30.0K | $-59.0K | $30.0K | $68.0K | $154.0K | $2.0K | $51.0K | $-41.0K | $17.0K | $9.0K | $-24.0K | |
| Pretax Income | $4M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Income Tax | $810.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| EPS (Basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| EPS (Diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| Shares (Basic) | 35,821,157 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| Shares (Diluted) | 39,919,557 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| EBITDA | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | · | · | $-15M | $-19M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $32M | $13M | $8M | $23M | $29M | $10M | $3M | $4M | $4M | $13M | $20M | |
| Receivables | $12M | $11M | $241.0K | $366.0K | $44.0K | $57.0K | $21.0K | $585.0K | $317.0K | $403.0K | $277.0K | $174.0K | |
| Inventory | $10M | $7M | $3M | $2M | $1M | $855.0K | $654.0K | $858.0K | $1M | $660.0K | $757.0K | $349.0K | |
| Prepaid Expense | $6M | $3M | $1M | $2M | $3M | $3M | $2M | $898.0K | $700.0K | $698.0K | $960.0K | $974.0K | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $222.0K | |
| Current Assets | $120M | $74M | $37M | $16M | $31M | $32M | $13M | $6M | $8M | $34M | $15M | $22M | |
| PP&E (Net) | $3M | $2M | $1M | $1M | $1M | $1M | $735.0K | $925.0K | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $8M | $7M | $6M | $6M | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Total Assets | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Accounts Payable | $3M | $961.0K | $1M | $2M | $638.0K | $2M | $5M | $8M | $4M | $594.0K | $284.0K | $748.0K | |
| Accrued Liabilities | $8M | $5M | $5M | $5M | $4M | $5M | $7M | $8M | $3M | $3M | $2M | $4M | |
| Current Liabilities | $11M | $6M | $16M | $15M | $6M | $10M | $16M | $18M | $8M | $36M | $6M | $5M | |
| Capital Leases | $835.0K | $933.0K | $0 | · | $207.0K | $450.0K | $197.0K | $0 | · | · | · | · | |
| Other Non-current Liabilities | $628.0K | $766.0K | $840.0K | $1M | $207.0K | · | $0 | $628.0K | $395.0K | $604.0K | $820.0K | $1M | |
| Total Liabilities | $12M | $8M | $23M | $24M | $21M | $13M | $21M | $22M | $8M | $37M | $7M | $6M | |
| Long-term Debt | · | $0 | $10M | $16M | · | · | · | · | · | · | · | · | |
| Common Stock | $347.0K | $331.0K | $228.0K | $100.0K | $79.0K | $60.0K | $1.0K | $0 | $2.0K | $0 | $14.0K | $97.0K | |
| Paid-in Capital | $639M | $600M | $521M | $452M | $433M | $417M | $365M | $329M | $326M | $278M | $270M | $265M | |
| Retained Earnings | $-529M | $-532M | $-505M | $-457M | $-421M | $-395M | $-371M | $-344M | $-325M | $-279M | $-261M | $-247M | |
| Treasury Stock | · | · | · | · | · | · | · | $0 | $51.0K | $51.0K | $51.0K | $51.0K | |
| AOCI | $575.0K | $82.0K | $135.0K | $-83.0K | $18.0K | $-104.0K | $28.0K | $50.0K | $42.0K | $-41.0K | $-8.0K | $20.0K | |
| Stockholders' Equity | $111M | $69M | $16M | $-6M | $12M | $22M | $-6M | $-15M | $678.0K | $-1M | $9M | $18M | |
| Liabilities + Equity | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Shares Outstanding | 34,691,671 | 33,061,002 | 22,761,554 | 10,046,571 | 7,906,728 | 5,996,101 | 67,091 | 14,715 | 228,139 | 11,750 | 1,360,239 | 9,708,841 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $23M | $-19M | $-31M | $-25M | $-23M | $-23M | $-24M | $-15M | $-15M | $-14M | $-16M | $-16M | |
| CapEx | $2M | $559.0K | $58.0K | $209.0K | $143.0K | $782.0K | $24.0K | $76.0K | $524.0K | $258.0K | $170.0K | $44.0K | |
| Investing Cash Flow | $-27M | $-981.0K | $-20M | $-209.0K | $-143.0K | $-782.0K | $-24.0K | $-76.0K | $-524.0K | · | · | · | |
| Net Debt Issued | · | $-11M | $-6M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $481.0K | $250.0K | $123.0K | $0 | $2M | $230.0K | $0 | $11M | · | · | · | · | |
| Stock Repurchased | $6M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-6M | $250.0K | $123.0K | · | $2M | $230.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $15M | $39M | $52M | $10M | $21M | $42M | $30M | $13M | $-11M | · | · | · | |
| Net Change in Cash | $11M | $20M | $874.0K | $-15M | $-2M | $19M | $7M | $-2M | $-26M | $-8M | $-8M | $-11M | |
| Taxes Paid | $2M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $21M | $-19M | $-31M | $-25M | $-23M | $-24M | $-24M | $-15M | · | · | $-17M | $-16M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 83.4% | 69.2% | 74.8% | · | · | · | · | · | · | 73.6% | 72.8% | |
| Operating Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| Net Margin | 3.2% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | -1625.9% | |
| Pretax Margin | 4.1% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | · | |
| EBITDA Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| ROA | 2.7% | -45.8% | -168.8% | -143.2% | -75.7% | -98.9% | -84.3% | -244.4% | · | · | -74.5% | -57.1% | |
| ROE | 2.5% | -68.2% | -235.5% | 657.5% | -216.7% | -190.6% | 70.5% | 194.1% | · | · | -109.9% | -72.0% | |
| ROIC | 0.46% | -18.1% | -242.0% | 577.8% | -205.3% | -96.5% | 313.2% | · | · | · | -176.8% | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 | 3.2 | 0.8 | 0.3 | · | · | 2.3 | 4.8 | |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 | 2.9 | 0.6 | 0.2 | · | · | 2.0 | 4.5 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 0.6 | 0.1 | 0.1 | · | · | · | · | · | · | 0.1 | 0.0 | |
| Inventory Turnover | 1.4 | 1.2 | 0.2 | 0.4 | 0.6 | 0.8 | 1.0 | 1.0 | · | · | 0.8 | 0.5 | |
| Receivables Turnover | 7.5 | 6.7 | 6.8 | 13.3 | · | · | · | · | · | · | 7.7 | 4.1 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.21 | $2.08 | $0.69 | $-0.74 | $1.51 | $3.68 | $-94.75 | $-1.46 | · | · | $0.40 | $1.87 | |
| Revenue / Share | $2.14 | $1.30 | $0.13 | $0.31 | · | · | · | · | · | · | $0.11 | $0.11 | |
| Cash Flow / Share | $0.56 | $-0.66 | $-1.93 | $-2.81 | · | $-7.89 | · | $-0.55 | · | · | $-1.02 | $-1.65 | |
| Cash / Share | $1.25 | $0.98 | $0.56 | $0.97 | $2.88 | $4.77 | $149.08 | $0.25 | · | · | $0.58 | $2.11 | |
| EPS (TTM) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 129.1% | 1701.7% | -24.1% | -23.5% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 215.3% | 118.7% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $37M | $2M | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Net Income TTM | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Market Cap | $350M | $398M | $95M | $28M | $61M | $107M | $1M | $2.01B | · | · | · | · | |
| P/E | 144.3 | -12.9 | -1.4 | -0.9 | -2.2 | -2.1 | -0.1 | -272.2 | · | · | · | · | |
| P/S | 4.1 | 10.7 | 45.9 | 10.5 | 17.2 | 34.8 | 0.5 | 649.3 | · | · | · | · | |
| P/B | 3.2 | 5.8 | 6.0 | -4.9 | 5.1 | 4.9 | -0.2 | -134.2 | · | · | · | · | |
| P / Tangible Book | 3.2 | 5.8 | 6.0 | · | 5.1 | 4.9 | · | · | · | · | · | · | |
| P / Cash Flow | 15.6 | -21.3 | -3.0 | -1.1 | -2.7 | -4.7 | -0.1 | -136.1 | · | · | · | · | |
| P / FCF | 16.7 | -20.7 | -3.0 | -1.1 | -2.7 | -4.5 | -0.1 | -135.4 | · | · | · | · | |
| Earnings Yield | 0.69% | -7.7% | -70.7% | -114.4% | -46.3% | -46.6% | -1613.3% | -0.37% | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $25M | $21M | $21M | $24M | $20M | $15M | $11M | $8M | $3M | $539.0K | $434.0K | $495.0K | $597.0K | $638.0K | $906.0K | |
| Cost of Revenue | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $903.0K | $171.0K | $133.0K | $150.0K | $181.0K | $238.0K | $235.0K | |
| Gross Profit | $26M | $21M | $18M | $18M | $21M | $17M | $13M | $10M | $6M | $2M | $368.0K | $301.0K | $345.0K | $416.0K | $400.0K | $671.0K | |
| R&D Expense | $10M | $10M | $9M | $8M | $7M | $5M | $3M | $4M | $3M | $4M | $5M | $5M | $4M | $5M | $4M | $4M | |
| SG&A Expense | $13M | $13M | $11M | $10M | $11M | $11M | $7M | $7M | $7M | $9M | $7M | $6M | $5M | $4M | $4M | $5M | |
| Operating Expenses | $24M | $23M | $20M | $18M | $18M | $16M | $10M | $11M | $10M | $13M | $12M | $11M | $8M | $9M | $8M | $9M | |
| Operating Income | $2M | $-2M | $-2M | $-388.0K | $3M | $642.0K | $3M | $-1M | $-4M | $-10M | $-11M | $-11M | $-8M | $-8M | $-8M | $-8M | |
| Other Non-op | $-17.0K | $-58.0K | $-7.0K | $-33.0K | $-34.0K | $4.0K | $-53.0K | $35.0K | $10.0K | $-22.0K | $-73.0K | $-5.0K | $6.0K | $13.0K | $27.0K | $26.0K | |
| Pretax Income | $3M | $-908.0K | $-1M | $375.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | · | · | · | · | · | · | |
| Income Tax | $491.0K | $162.0K | $562.0K | $-455.0K | $508.0K | $195.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $3M | $-1M | $-2M | $830.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | $-11M | $-20M | $-7M | $-9M | $-8M | $-9M | |
| EPS (Basic) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.08 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| EPS (Diluted) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.07 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| Shares (Basic) | 35,891,915 | 36,021,210 | · | 36,383,277 | 35,786,813 | 34,642,641 | · | 28,738,307 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| Shares (Diluted) | 39,761,480 | 36,021,210 | · | 40,056,814 | 40,262,764 | 39,511,120 | · | 32,345,672 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| EBITDA | $2M | $-2M | · | $-388.0K | $3M | $642.0K | · | $-1M | $-4M | $-10M | · | $-11M | $-8M | $-8M | · | $-8M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $41M | $43M | $42M | $34M | $13M | $32M | $8M | $15M | $12M | $13M | $40M | $15M | $24M | $8M | $10M | |
| Receivables | $16M | $14M | $12M | $14M | $16M | $14M | $11M | $7M | $4M | $2M | $241.0K | $205.0K | $127.0K | $458.0K | $366.0K | $537.0K | |
| Inventory | $12M | $10M | $10M | $11M | $11M | $7M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Prepaid Expense | $7M | $7M | $6M | $7M | $6M | $4M | $3M | $1M | $1M | $1M | $1M | $3M | $2M | $2M | $2M | $2M | |
| Current Assets | $131M | $120M | $120M | $121M | $113M | $84M | $74M | $29M | $31M | $34M | $37M | $46M | $19M | $29M | $16M | $18M | |
| PP&E (Net) | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| PP&E (Gross) | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Total Assets | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Accounts Payable | $4M | $3M | $3M | $2M | $5M | $2M | $961.0K | $937.0K | $3M | $1M | $1M | $753.0K | $966.0K | $2M | $2M | $3M | |
| Accrued Liabilities | $9M | $7M | $8M | $6M | $6M | $4M | $5M | $6M | $4M | $4M | $5M | $5M | $6M | $7M | $5M | $5M | |
| Current Liabilities | $13M | $11M | $11M | $8M | $10M | $5M | $6M | $22M | $12M | $13M | $16M | $14M | $11M | $13M | $15M | $14M | |
| Capital Leases | $2M | $815.0K | $835.0K | $855.0K | $877.0K | $906.0K | $933.0K | $963.0K | $989.0K | $1M | $0 | · | · | · | · | · | |
| Other Non-current Liabilities | $327.0K | $615.0K | $628.0K | $582.0K | $578.0K | $896.0K | $766.0K | $563.0K | $632.0K | $962.0K | $840.0K | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $16M | $12M | $12M | $9M | $12M | $7M | $8M | $23M | $30M | $21M | $23M | $23M | $21M | $25M | $24M | $25M | |
| Long-term Debt | · | · | · | · | · | · | · | $2M | $4M | $7M | $10M | · | · | · | $16M | · | |
| Common Stock | $346.0K | $344.0K | $347.0K | $353.0K | $350.0K | $334.0K | $331.0K | $280.0K | $279.0K | $254.0K | $228.0K | $197.0K | $153.0K | $101.0K | $100.0K | $86.0K | |
| Paid-in Capital | $648M | $642M | $639M | $641M | $632M | $610M | $600M | $536M | $534M | $530M | $521M | $519M | $473M | $453M | $452M | $442M | |
| Retained Earnings | $-527M | $-530M | $-529M | $-527M | $-528M | $-530M | $-532M | $-528M | $-530M | $-516M | $-505M | $-494M | $-474M | $-466M | $-457M | $-447M | |
| AOCI | $258.0K | $571.0K | $575.0K | $875.0K | $592.0K | $381.0K | $82.0K | $11.0K | $8.0K | $157.0K | $135.0K | $-59.0K | $-64.0K | $-64.0K | $-83.0K | $-57.0K | |
| Stockholders' Equity | $121M | $113M | $111M | $115M | $105M | $80M | $69M | $9M | $4M | $15M | $16M | $25M | $-242.0K | $-13M | $-6M | $-5M | |
| Liabilities + Equity | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Shares Outstanding | 34,636,252 | 34,465,087 | 34,691,671 | 35,308,939 | 34,955,974 | 33,436,612 | 33,061,002 | 28,019,599 | 27,931,393 | 25,439,319 | 22,761,554 | 19,688,991 | 15,250,469 | 10,046,571 | 10,046,571 | 8,597,682 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6M | $857.0K | $8M | $5M | $7M | $2M | $-1M | $-4M | $-4M | $-10M | $-8M | $-9M | $-10M | $-4M | $-7M | $-5M | |
| CapEx | $503.0K | $570.0K | $550.0K | $459.0K | $398.0K | $140.0K | $229.0K | $216.0K | $101.0K | $13.0K | $19.0K | $-1.0K | $40.0K | $0 | $0 | $68.0K | |
| Investing Cash Flow | $-504.0K | $-571.0K | $-561.0K | $-466.0K | $-415.0K | $-25M | $-15M | $-697.0K | $10M | $5M | $-20M | $1.0K | $-40.0K | $0 | $0 | $-68.0K | |
| Stock Issued | $0 | $389.0K | $0 | $243.0K | $0 | $238.0K | $0 | $175.0K | $0 | $75.0K | $0 | $76.0K | $0 | $47.0K | $0 | $0 | |
| Stock Repurchased | $11.0K | $3M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $-3M | · | · | · | $238.0K | · | · | · | $75.0K | · | · | · | $47.0K | · | · | |
| Financing Cash Flow | $962.0K | $-2M | $-6M | $3M | $15M | $3M | $40M | $-2M | $-3M | $4M | $1.0K | $35M | $7.0K | $17M | $5M | $5M | |
| Net Change in Cash | $6M | $-2M | $2M | $7M | $22M | $-20M | $24M | $-6M | $3M | $-886.0K | $-28M | $26M | $-10M | $12M | $-2M | $-372.0K | |
| Taxes Paid | · | · | $228.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $287.0K | · | · | · | $2M | · | · | · | $-10M | · | · | · | $-4M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 85.0% | · | 87.2% | 86.3% | 85.6% | · | 85.4% | 80.4% | 71.2% | · | 69.3% | 69.7% | 69.7% | · | · | |
| Operating Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| Net Margin | 9.2% | -4.3% | · | 4.0% | 11.2% | 5.4% | · | 16.6% | -176.9% | -354.0% | · | -4686.6% | -1455.0% | -1507.5% | · | · | |
| Pretax Margin | 10.8% | -3.6% | · | 1.8% | 13.3% | 6.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| ROA | 2.1% | -1.0% | · | 1.1% | 3.6% | 1.7% | · | 4.7% | -50.0% | -33.3% | · | -60.0% | -34.2% | -31.1% | · | -31.1% | |
| ROE | 2.4% | -1.1% | · | 1.4% | 4.9% | 2.2% | · | 11.2% | -695.8% | -1439.2% | · | -208.9% | 466.5% | 229.3% | · | -262.5% | |
| ROIC | 1.7% | -1.7% | · | -0.75% | 2.1% | 0.68% | · | · | · | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.8 | 11.2 | · | 15.1 | 10.9 | 16.0 | · | 1.3 | 2.6 | 2.5 | · | 3.3 | 1.8 | 2.2 | · | 1.3 | |
| Quick Ratio | 4.8 | 5.2 | · | 6.9 | 4.8 | 5.1 | · | 0.7 | 1.5 | 1.0 | · | 2.9 | 1.3 | 1.8 | · | 0.7 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | · | |
| Inventory Turnover | 0.3 | 0.4 | · | 0.3 | 0.4 | 0.5 | · | 0.4 | 0.3 | 0.3 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.8 | 1.8 | · | 2.0 | 2.5 | 2.6 | · | 3.1 | 4.0 | 3.1 | · | 1.2 | 1.8 | 1.9 | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.50 | $3.27 | · | $3.25 | $3.00 | $2.40 | · | $0.31 | $0.15 | $0.57 | · | $1.26 | $-0.02 | $-1.30 | · | $-0.61 | |
| Revenue / Share | $0.73 | $0.69 | · | $0.51 | $0.60 | $0.50 | · | $0.35 | $0.27 | $0.13 | · | $0.02 | $0.04 | $0.05 | · | · | |
| Cash Flow / Share | · | $0.02 | · | · | · | $0.06 | · | · | · | $-0.39 | · | · | · | $-0.37 | · | · | |
| Cash / Share | $1.37 | $1.20 | · | $1.18 | $0.98 | $0.38 | · | $0.30 | $0.53 | $0.46 | · | $2.06 | $0.95 | $2.41 | · | $1.14 | |
| EPS (TTM) | $0.01 | $0.01 | · | $0.06 | $0.10 | $-0.45 | · | $-1.32 | $-2.52 | $-2.62 | · | $-3.31 | $-3.13 | $-3.79 | · | $-3.95 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $95M | $90M | · | $80M | $70M | $54M | · | $23M | $12M | $5M | · | $2M | $3M | $3M | · | · | |
| Net Income TTM | $532.0K | $561.0K | · | $1M | $2M | $-14M | · | $-34M | $-56M | $-50M | · | $-45M | $-34M | $-37M | · | $-33M | |
| Market Cap | $436M | $320M | · | $380M | $475M | $426M | · | $253M | $234M | $121M | · | $80M | $89M | $58M | · | $28M | |
| P/E | 1259.0 | 928.0 | · | 179.2 | 136.0 | -28.3 | · | -6.8 | -3.3 | -1.8 | · | -1.2 | -1.9 | -1.5 | · | -0.8 | |
| P/S | 4.6 | 3.5 | · | 4.8 | 6.8 | 7.9 | · | 11.2 | 19.7 | 26.3 | · | 36.8 | 33.7 | 19.7 | · | · | |
| P/B | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | -367.4 | -4.4 | · | -5.2 | |
| P / Tangible Book | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | · | · | · | · | |
| P / Cash Flow | · | 373.2 | · | · | · | 193.2 | · | · | · | -12.7 | · | · | · | -13.5 | · | · | |
| Earnings Yield | 0.08% | 0.11% | · | 0.56% | 0.74% | -3.5% | · | -14.6% | -30.1% | -54.9% | · | -81.7% | -53.7% | -65.9% | · | -123.4% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $85M | $37M | $2M | $3M | $4M |
| Brüt Kâr Marjı % | 86.2% | 83.4% | 69.2% | 74.8% | · |
| Faaliyet Kâr Marjı % | 0.77% | -33.4% | -1849.0% | -1245.0% | · |
| Net Gelir | $3M | $-26M | $-48M | $-37M | $-26M |
| Seyreltilmiş Hisse Başı Kâr | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 |
| Cari Oran | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $21M | $-19M | $-31M | $-25M | $-23M |
Kurumsal Sahipler (13F) 139 dosya · $243.2M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
139
Tutulan Değer
$243.2M
Yeni pozisyonlar
21
Çıkan pozisyonlar
17
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 21 (-10 önceki Ç'ye göre) | 17 (-3 önceki Ç'ye göre) | 48 (+10 önceki Ç'ye göre) | 29 (-8 önceki Ç'ye göre) | +1.1M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $41.551.898 | 3.300.389 | 17,08% | Hisse senetleri |
| BlackRock, Inc. | $34.078.638 | 2.706.802 | 14,01% | Hisse senetleri |
| VANGUARD GROUP INC | $16.890.806 | 1.672.357 | 6,94% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.375.500 | 1.221.247 | 6,32% | Hisse senetleri |
| Propel Bio Management, LLC | $10.971.681 | 871.460 | 4,51% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $9.232.592 | 733.115 | 3,80% | Hisse senetleri |
| STATE STREET CORP | $8.552.135 | 679.280 | 3,52% | Hisse senetleri |
| ALGERT GLOBAL LLC | $7.311.114 | 580.708 | 3,01% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $7.130.611 | 566.371 | 2,93% | Hisse senetleri |
| Divisadero Street Capital Management, LP | $6.292.432 | 499.796 | 2,59% | Hisse senetleri |
| MORGAN STANLEY | $5.136.506 | 407.983 | 2,11% | Hisse senetleri |
| ExodusPoint Capital Management, LP | $4.530.940 | 359.884 | 1,86% | Hisse senetleri |
| Private Wealth Advisors, LLC | $3.913.765 | 310.863 | 1,61% | Hisse senetleri |
| Simplify Asset Management Inc. | $3.333.454 | 264.770 | 1,37% | Hisse senetleri |
| NORTHERN TRUST CORP | $3.174.040 | 252.108 | 1,30% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $3.151.429 | 250.312 | 1,30% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $2.825.007 | 224.385 | 1,16% | Hisse senetleri |
| MARSHALL WACE, LLP | $2.756.745 | 218.963 | 1,13% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $2.647.652 | 210.298 | 1,09% | Hisse senetleri |
| KENNEDY CAPITAL MANAGEMENT LLC | $2.570.160 | 204.143 | 1,06% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.435.510 | 193.448 | 1,00% | Hisse senetleri |
| Ikarian Capital, LLC | $2.337.548 | 185.667 | 0,96% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $2.290.159 | 181.903 | 0,94% | Hisse senetleri |
| Nuveen, LLC | $2.286.281 | 181.595 | 0,94% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $2.177.981 | 172.993 | 0,90% | Hisse senetleri |
| CIBC WORLD MARKET INC. | $2.054.789 | 163.208 | 0,84% | Hisse senetleri |
| Caption Management, LLC | $1.894.795 | 150.500 | 0,78% | Satım opsiyonu |
| Lane Generational LLC | $1.884.257 | 149.663 | 0,77% | Hisse senetleri |
| HSBC HOLDINGS PLC | $1.705.848 | 135.600 | 0,70% | Hisse senetleri |
| Man Group plc | $1.617.752 | 128.495 | 0,67% | Hisse senetleri |
| Cubist Systematic Strategies, LLC | $1.562.514 | 145.350 | 0,64% | Hisse senetleri |
| Diametric Capital, LP | $1.546.568 | 122.841 | 0,64% | Hisse senetleri |
| Bank of New York Mellon Corp | $1.361.725 | 108.159 | 0,56% | Hisse senetleri |
| BARCLAYS PLC | $1.359.090 | 107.950 | 0,56% | Hisse senetleri |
| Caption Management, LLC | $1.259.000 | 100.000 | 0,52% | Alım opsiyonu |
| Capital Advisors Wealth Management, LLC | $1.170.870 | 93.000 | 0,48% | Hisse senetleri |
| Jump Financial, LLC | $1.108.360 | 88.035 | 0,46% | Hisse senetleri |
| Jefferies Financial Group Inc. | $1.057.308 | 83.980 | 0,43% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.050.824 | 83.465 | 0,43% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.022.308 | 81.200 | 0,42% | Alım opsiyonu |
| Stonepine Capital Management, LLC | $1.000.000 | 100.000 | 0,41% | Alım opsiyonu |
| Caption Management, LLC | $978.243 | 77.700 | 0,40% | Hisse senetleri |
| Russell Investments Group, Ltd. | $851.813 | 67.658 | 0,35% | Hisse senetleri |
| FOX RUN MANAGEMENT, L.L.C. | $776.526 | 61.678 | 0,32% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $774.587 | 61.524 | 0,32% | Hisse senetleri |
| Quantbot Technologies LP | $749.860 | 59.560 | 0,31% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $728.885 | 57.894 | 0,30% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $725.864 | 57.654 | 0,30% | Hisse senetleri |
| Creative Planning | $609.784 | 48.434 | 0,25% | Hisse senetleri |
| UBS Group AG | $525.179 | 41.714 | 0,22% | Hisse senetleri |
Aktivistler ve %5+ sahipler 17 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc., SALAMON STEVEN A J, Aharon Gil, Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P. ×15 başvurular | 10 Şubat 2026 | 9,90% | Değişiklik | · | SEC |
| Açıklanmayan raporlama kişisi | 16 Aralık 2022 | · | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 27 Temmuz 2022 | · | İlk başvuru | Pasif yatırım | SEC |
| Laddcap Value Partners LP S.S. or, Laddcap Value Associates LLC S.S. or, Laddcap Value Advisors LLC S.S. or, Robert Ladd S.S. or ×2 başvurular | 02 Ağustos 2010 | · | İlk başvuru | · | SEC |
| Robert Ladd | 18 Ekim 2006 | · | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 28 Temmuz 2006 | · | İlk başvuru | Yönetim kurulu kampanyası | SEC |
| Açıklanmayan raporlama kişisi | 11 Temmuz 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 14 Haziran 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 08 Haziran 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 24 Mayıs 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 28 Nisan 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 10 Ocak 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 06 Ocak 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 14 Aralık 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 10 Kasım 2005 | · | İlk başvuru | Yönetim kurulu kampanyası | SEC |
| Açıklanmayan raporlama kişisi | 24 Ekim 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 17 Ekim 2005 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 49 içeriden öğrenenler · 13 yöneticiler · 17 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Jennifer K. Simpson | President and CEO | 08 Mayıs 2020 C | 25.021 | 0 | 0 | $0 |
| Sandra Pennell | Chief Financial Officer | 06 Mart 2026 P | 77.018 | 1 | 0 | $50.018 |
| Barbra Keck | Chief Financial Officer, Secretary | 08 Mayıs 2020 C | 12.851 | 0 | 0 | $0 |
| Paul M Feinstein | Chief Financial Officer | 30 Kasım 2007 A | 3.375 | 0 | 0 | $0 |
| Martha S. Rook | CHIEF OPERATING OFFICER | 17 Şubat 2026 A | · | 0 | 0 | $0 |
| John Purpura | CHIEF OPERATING OFFICER | 08 Şubat 2023 A | 41.526 | 0 | 0 | $0 |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | 29 Mayıs 2007 P | 160.375 | 0 | 0 | $0 |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 17 Şubat 2026 A | 74.330 | 0 | 0 | $0 |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 17 Şubat 2026 A | 18.582 | 0 | 0 | $0 |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | 17 Şubat 2026 A | 168.882 | 0 | 0 | $0 |
| Johnny John | SVP CLINICAL DEV & MED AFFAIRS | 08 Şubat 2023 A | · | 0 | 0 | $0 |
| Anthony Dias | VP FINANCE | 08 Şubat 2023 A | · | 0 | 0 | $0 |
| Christine Padula | Interim Principal Accounting Officer | 01 Eylül 2021 A | · | 0 | 0 | $0 |
| Aharon Gil | Yönetim kurulu üyesi | 13 Mayıs 2026 A | 3.413.468 | 0 | 0 | $0 |
| John Richard Sylvester | Yönetim kurulu üyesi | 13 Mayıs 2026 A | 14.936 | 1 | 0 | $38.992 |
| Bridget A Martell | Yönetim kurulu üyesi | 13 Mayıs 2026 A | · | 0 | 0 | $0 |
| Steven A J Salamon | Yönetim kurulu üyesi | 13 Mayıs 2026 A | 3.413.468 | 0 | 0 | $0 |
| Roger G Stoll PHD | Yönetim kurulu üyesi | 23 Mayıs 2024 A | 9.309 | 0 | 0 | $0 |
| Rosalind Advisors, Inc. | Yönetim kurulu üyesi | 14 Aralık 2022 P | 459.315 | 0 | 0 | $0 |
| Marco Taglietti | Yönetim kurulu üyesi | 08 Mayıs 2020 C | 6.000 | 0 | 0 | $0 |
| William Dodge Rueckert | Yönetim kurulu üyesi | 08 Mayıs 2020 C | 6.014 | 0 | 0 | $0 |
| Simon Pedder | Yönetim kurulu üyesi | 01 Şubat 2019 A | · | 0 | 0 | $0 |
| Laura A Philips | Yönetim kurulu üyesi | 23 Temmuz 2015 P | 205.299 | 0 | 0 | $0 |
| Harold S Koplewicz | Yönetim kurulu üyesi | 10 Haziran 2015 A | 45.052 | 0 | 0 | $0 |
| Dennis Langer | Yönetim kurulu üyesi | 10 Haziran 2015 A | 20.000 | 0 | 0 | $0 |
| Jonathan Lewis | Yönetim kurulu üyesi | 30 Haziran 2008 A | 10.000 | 0 | 0 | $0 |
| Mark Corigliano | Yönetim kurulu üyesi | 16 Nisan 2007 M | 198.176 | 0 | 0 | $0 |
| Daniel Isdaner | Yönetim kurulu üyesi | 16 Nisan 2007 M | 253.668 | 0 | 0 | $0 |
| Elizabeth Czerepak | · | 13 Mayıs 2026 A | · | 0 | 0 | $0 |
| Gerard J Michel | · | 02 Mart 2026 P | 342.034 | 2 | 0 | $198.447 |
| Laura Brege | · | 07 Temmuz 2014 A | 11.678 | 0 | 0 | $0 |
| Tasos Konidaris | · | 07 Temmuz 2014 A | 11.678 | 0 | 0 | $0 |
| Gabriel Leung | · | 07 Temmuz 2014 A | 21.485 | 0 | 0 | $0 |
| Douglas G Watson | · | 07 Temmuz 2014 A | 136.664 | 0 | 0 | $0 |
| Graham G Miao | · | 14 Kasım 2013 A | 54.000 | 0 | 0 | $0 |
| Peter J Graham | · | 14 Kasım 2013 A | 15.000 | 0 | 0 | $0 |
| William M Appling | · | 15 Temmuz 2013 A | · | 0 | 0 | $0 |
| Krishna Kandarpa | · | 11 Mart 2013 A | 159.000 | 0 | 0 | $0 |
| Harold Mapes | · | 11 Mart 2013 A | 17.000 | 0 | 0 | $0 |
| Eamonn P Hobbs | · | 11 Mart 2013 A | 162.000 | 0 | 0 | $0 |
| Agustin V Gago | · | 11 Mart 2013 A | 80.944 | 0 | 0 | $0 |
| Robert Ladd | · | 15 Haziran 2012 A | 69.534 | 0 | 0 | $0 |
| David Mcdonald | · | 10 Mart 2011 A | 47.706 | 0 | 0 | $0 |
| Pamela Reilly Contag | · | 01 Aralık 2010 A | 8.507 | 0 | 0 | $0 |
| Richard Taney | · | 10 Aralık 2009 A | 211.485 | 0 | 0 | $0 |
| Jason Andrew Rifkin | · | 12 Ekim 2009 A | · | 0 | 0 | $0 |
| KOLY M S /FA/ | · | 26 Ocak 2007 X | 775.360 | 0 | 0 | $0 |
| Victor Nevins | · | 12 Ekim 2006 M | 180.007 | 0 | 0 | $0 |
| VENKOL TRUST | · | 10 Kasım 2004 J | 892.649 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 16 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IWC · iShares Trust | 0,11% | 97.206 SH | 11 Eylül 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 21.358 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,02% | 743.359 SH | 11 Eylül 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 2.376 SH | 01 Ekim 2026 | Günlük |
| RSSL · Global X Funds | 0,01% | 13.736 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 165.177 SH | 19 Ağustos 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,01% | 70.373 NS | 31 Temmuz 2026 | N-PORT |
| IWO · iShares Trust | 0,00% | 39.522 SH | 11 Eylül 2026 | Günlük |
| DFSU · Dimensional ETF Trust | 0,00% | 3.297 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 43.746 SH | 11 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,00% | 12.489 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 304.809 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 889.410 SH | 19 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.438 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.475 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 228.409 SH | 11 Eylül 2026 | Günlük |
DCTH Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 12 analist
AL
Medyan hedef
$22.00
+45,4%
3 25,0%
Güçlü Al
8 66,7%
Al
1 8,3%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
5 analist · 2026-09-29Ortalama hedef $24.00 +58,6%
← Tüm hedeflerin altında
Mevcut fiyat $15.13
Düşük$21.00
Ortalama$24.00
Yüksek$32.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| DCTH | $350M | 144.3 | 129.1% | 3.2% | 2.5% | 86.2% |
| SSII | · | -94.7 | 105.7% | · | · | · |
| SENS | $228M | -3.3 | 56.9% | -196.0% | -88.7% | 44.7% |
| TCMD | $651M | 35.4 | 12.5% | 5.8% | 9.2% | 75.9% |
| SGHT | $424M | -10.7 | -3.1% | -49.7% | -57.4% | 86.2% |
| NPCE | $518M | -23.4 | 25.1% | -21.5% | -111.6% | 77.2% |
| SI | $295M | -3.1 | 49.6% | -85.3% | -129.1% | 76.5% |
| CARL | $329M | -5.8 | 85.9% | -58.7% | -375.2% | 75.3% |
| OFIX | $604M | -6.5 | 2.9% | -11.2% | -20.3% | 68.8% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 6, 2026